Melatonin for Kids Is Now Prescription-Only in Canada: The Qualifier Change Nobody Read Properly

If your business sells or imports any product that contains melatonin, a quiet change to Health Canada's Prescription Drug List has already changed your compliance obligations. As of 2 June 2026, melatonin sold for sleep-related use in anyone under 18 years of age is a prescription drug under the Food and Drug Regulations. There was no transition period. The change took effect the day it was posted.

This is not a future deadline you can plan around. It is a rule that is in force now. Yet most of the early coverage described it incorrectly, calling it a change about insomnia, or a change only for children with a specific diagnosis. The real wording is broader than that, and the gap between what people think changed and what actually changed is where compliance risk lives. This article quotes the qualifier word for word, explains who is affected, and sets out exactly what natural health product (NHP) licence holders should check today.

What Health Canada actually changed

In short: Health Canada changed the qualifier attached to the melatonin or its salts listing on the human use part of the Prescription Drug List. The new qualifier captures all sleep-related use in children and adolescents under 18. Any drug containing melatonin that is sold for that purpose is now a prescription drug under the Food and Drug Regulations, which means it needs a prescription and cannot be sold as an over-the-counter natural health product.

The notice of amendment was published on 2 June 2026 under file number 26-103029-408. It followed a notice of intent dated 26 May 2026 and a public consultation that ran from 16 September to 30 December 2025. The table below shows the previous listing and the new listing side by side, quoted exactly from Health Canada.

Element	Previous listing (effective 2025-09-09)	New listing (effective 2026-06-02)
Qualifier (verbatim)	when sold for the treatment of insomnia in those 2 to under 18 years of age with Autism Spectrum Disorder and / or Smith-Magenis syndrome	when sold for sleep-related use in children and adolescents under 18 years of age
What triggers prescription status	Insomnia treatment in a defined, diagnosed group	Any sleep-related use in anyone under 18
Lower age bound	2 years	None
Diagnosis condition	ASD and / or Smith-Magenis syndrome	None

Why sleep-related use is much broader than insomnia

Why it matters: the scope of the qualifier decides which products are caught. Three shifts made the new qualifier far wider than the one it replaced, and each one pulls more products into prescription status.

The word insomnia is gone. Sleep-related use is a wider idea than treating a diagnosed sleep disorder. A product marketed to help a child settle, fall asleep faster, or sleep through the night can fall within sleep-related use even if it never mentions insomnia.

The lower age bound of 2 years is gone. The old qualifier only applied from age 2. The new one applies to anyone under 18, so infants and toddlers are now inside the scope as well.

The diagnosis condition is gone. The old qualifier only bit where the child had Autism Spectrum Disorder or Smith-Magenis syndrome. The new qualifier has no diagnosis limit at all. Sleep-related use in any child or adolescent is enough.

Describing this change as melatonin for insomnia in children materially understates it. The correct reading is: melatonin sold for any sleep-related use in anyone under 18 is now prescription-only.

There is no transition period

What to do: assume you are already exposed and act now, because Health Canada gave no grace period. The notice of intent states plainly: The 6-month transition period under the Technical Barriers to Trade Agreement will be omitted. The posting date and the effective date are the same, 2 June 2026.

Health Canada could omit the usual transition because there was nothing on the market to disrupt. There are no non-prescription drugs and no NHPs containing melatonin authorized for children or adolescents in Canada. In practice this means a company cannot rely on a sell-through window. If a product could be read as sold for paediatric sleep-related use, the exposure exists today.

What it means for your NHP licence

Direct answer: your currently licensed adult melatonin NHPs are not affected. Health Canada states that the change does not affect any currently licensed melatonin-containing NHPs, because these products are all indicated for adults only and remain subject to the Natural Health Products Regulations. If your product is authorized and marketed for adults, your NPN stands.

The exposure sits in how a product is sold for its use, not only in what its licence says. A melatonin product authorized for adults can drift into the prescription qualifier if the label, package, website, retail listing, or advertising invites paediatric sleep use. This is where a careful review of your NHP compliance and a clear understanding of the line between non-prescription and prescription authorization pays off.

Two boundaries are worth noting. First, Slenyto, the one prescription drug authorized under the Food and Drug Regulations to treat insomnia in children and adolescents aged 2 to under 18 with Autism Spectrum Disorder or Smith-Magenis syndrome, continues to fall within the amended qualifier. Second, the change was made to the human use part of the Prescription Drug List only. It was not added to the veterinary part, so veterinary melatonin products are not caught by this amendment.

The legal basis: paragraph C.01.040.3(a)

Health Canada concluded that paragraph C.01.040.3(a) of the Food and Drug Regulations applies to melatonin products for paediatric sleep-related use. That paragraph provides for prescription status where supervision by a practitioner is necessary for the diagnosis, treatment, mitigation, or prevention of a condition or its symptoms, or to monitor the condition or the use of the drug. The department's guidance on determining prescription status explains the factors it weighs.

Health Canada gave three reasons a practitioner should supervise paediatric melatonin use: to rule out underlying health issues that could be causing sleep problems; to give guidance on sleep hygiene, which the department says should be tried before using melatonin; and to set the right dose for the child based on age, medical history, and other medications.

The route to the paediatric market

What to do if you want the paediatric market: Health Canada says sponsors who wish to market melatonin for sleep-related uses in the paediatric population should seek authorization under the Food and Drug Regulations with the Pharmaceutical Drugs Directorate. That is a drug submission pathway, not a natural health product one. Applicants who only want to serve adults should continue to submit a natural health product licence application to the Natural and Non-prescription Health Products Directorate. If you are weighing these routes, our overviews of NHP licensing and our regulatory affairs and licensing services are useful starting points.

Compliance checklist

Use this checklist to find and close melatonin exposure across your portfolio:

Inventory every melatonin-containing product you sell or import, including NHPs, drugs, and third-party listings.
Confirm each product's authorization (NPN, DIN, or none) and the population it is indicated for.
Check whether any label, claim, image, or sales channel could be read as sold for sleep-related use in anyone under 18.
Remove or revise any paediatric sleep representation from labels, packaging, websites, retail listings, and advertising.
Confirm your NHP indications remain adult-only and consistent with the NNHPD Melatonin oral and sublingual monographs.
Document, in writing, that no product is marketed for children or adolescents under 18 for a sleep-related use.
If you want the paediatric market, plan a Food and Drug Regulations submission with the Pharmaceutical Drugs Directorate.
Brief sales, marketing, and e-commerce teams that the change took effect on 2 June 2026 with no transition period.
Screen incoming imports and marketplace listings for paediatric melatonin sleep claims before they reach shelves.

Common mistakes

Reading the change as only about insomnia, and missing that any sleep-related use is now caught.
Assuming a transition period exists. It does not. The rule applied on the posting date.
Believing an adult NPN protects a product that is being marketed, even indirectly, for children's sleep.
Overlooking gummies, liquids, and flavoured formats that read as child-friendly even when the label targets adults.
Forgetting online channels and marketplace copy, where third-party sellers may add paediatric sleep claims you did not write.

Frequently asked questions

Is melatonin prescription-only in Canada now?

Not for adults. Melatonin remains available as an adult natural health product. What changed is that melatonin sold for sleep-related use in children and adolescents under 18 is a prescription drug under the Food and Drug Regulations, effective 2 June 2026.

Can I sell melatonin gummies for kids in Canada?

Not as an over-the-counter natural health product. A melatonin product sold for sleep-related use in anyone under 18 now requires authorization as a prescription drug under the Food and Drug Regulations through the Pharmaceutical Drugs Directorate.

Does this affect my existing adult melatonin NPN?

No. Health Canada states the change does not affect currently licensed melatonin NHPs, which are all indicated for adults only and remain under the Natural Health Products Regulations. Your risk is only if a product could be read as sold for paediatric sleep use.

Was there a transition period?

No. Health Canada omitted the 6-month Technical Barriers to Trade transition period. The posting date and the effective date are the same, 2 June 2026, so the rule applied immediately.

Does the change apply to veterinary melatonin products?

No. The amendment was made to the human use part of the Prescription Drug List. It was not added to the veterinary part, so veterinary melatonin products are not affected by this change.

What is the legal basis for the change?

Paragraph C.01.040.3(a) of the Food and Drug Regulations, which supports prescription status where practitioner supervision is necessary to diagnose, treat, or monitor a condition or the use of the drug.

How MFLRC can help

MF License and Regulatory Consultants helps NHP and drug companies stay ahead of changes like this one. We run indication and claim risk screening across a whole portfolio, review labels and packaging against the current Prescription Drug List, and assess exposure product by product. We also support NHP labelling and broader natural health product compliance work, from gap assessments and SOP development to GMP and site licence readiness. If you want the paediatric market, we can map the Food and Drug Regulations submission strategy with the Pharmaceutical Drugs Directorate.

If any product in your portfolio could be read as sold for sleep-related use in anyone under 18, that exposure exists today, because there was no transition period. MFLRC reviews NHP indications and labels against the current Prescription Drug List so you can act before Health Canada does.

Book a consultation with MFLRC

Conclusion

The melatonin qualifier change is small in wording and large in effect. By dropping the word insomnia, the age floor, and the diagnosis condition, Health Canada turned a narrow listing into a broad one that catches any melatonin sold for sleep-related use in anyone under 18. With no transition period, the safe assumption is that your obligations already changed. Review your portfolio, clean up any paediatric sleep signals, and keep a written record of your assessment. That is the difference between a controlled position and an inspection finding.